{"id":19165,"date":"2024-05-04T15:39:27","date_gmt":"2024-05-04T19:39:27","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=19165"},"modified":"2025-01-29T09:23:02","modified_gmt":"2025-01-29T14:23:02","slug":"sentynl","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/nl\/2024\/05\/04\/sentynl\/","title":{"rendered":"PRF werkt nu samen met Sentynl Therapeutics, de nieuwe wereldwijde eigenaar van de lonafarnib-behandeling (Zokinvy\u00a9)"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_image src=&#8221;https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/static1.squarespace.webp&#8221; title_text=&#8221;static1.squarespace&#8221; url=&#8221;https:\/\/www.charitynavigator.org\/ein\/043460220&#8243; align=&#8221;center&#8221; admin_label=&#8221;Sentynl&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; width=&#8221;50%&#8221; max_width=&#8221;50%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.24.3&#8243; text_font_size=&#8221;18px&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Met ingang van vrijdag 3 mei<sup>rd<\/sup>, 2024, <a href=\"https:\/\/url2.mailanyone.net\/scanner?m=1rzcKM-0009Dy-3G&amp;d=4%7Cmail%2F90%2F1713963600%2F1rzcKM-0009Dy-3G%7Cin2m%7C57e1b682%7C18374732%7C14629442%7C662903CE3D97FA99FA9E3F52842D032F&amp;o=%2Fphte%3A%2Fstsonnt%2F.cmyl&amp;s=pj636_P9eRvPUtyP8VtSjuVNKfg\">Sentynl Therapeutics, Inc.<\/a> (Sentynl), een Amerikaans biofarmaceutisch bedrijf dat volledig eigendom is van Zydus Lifesciences, Ltd, heeft de wereldwijde rechten op lonafarnib (Zokinvy) verworven van Eiger BioPharmaceuticals (Eiger). Zokinvy\u00ae wordt wereldwijd verstrekt aan families die het medicijn gebruiken als behandeling voor progeria.<\/p>\n<p>Sentynl, gevestigd in San Diego, Californi\u00eb, richt zich op het leveren van nieuwe biofarmaceutische medicijnen die het leven van mensen met een zeldzame ziekte verlengen, verbeteren of verrijken (https:\/\/sentynl.com\/). PRF is dankbaar voor de succesvolle samenwerking met Eiger en verheugd om nu de krachten te bundelen met Sentynl. PRF zal nauw met hen samenwerken, zoals we met Eiger deden, om het bedrijf te helpen bij zijn inspanningen om ononderbroken levering van Zokinvy voor pati\u00ebnten over de hele wereld te garanderen.\u00a0\u00a0<\/p>\n<p>Een link naar het persbericht van Sentynl over dit nieuws is te vinden <a href=\"https:\/\/www.prnewswire.com\/news-releases\/sentynl-therapeutics-announces-global-acquisition-of-zokinvy-lonafarnib-for-treatment-of-hutchinson-gilford-progeria-syndrome-from-eiger-biopharmaceuticals-302135968.html\">hier<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>Vanaf vrijdag 3 mei is Sentynl Therapeutics verantwoordelijk voor de productie en distributie van Zokinvy, de door de FDA goedgekeurde behandeling voor Progeria. <\/p>","protected":false},"author":2,"featured_media":18808,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,1],"tags":[],"class_list":["post-19165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sentynl I The Progeria esearch Foundation<\/title>\n<meta name=\"description\" content=\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/nl\/2024\/05\/04\/sentynl\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sentynl I The Progeria esearch Foundation\" \/>\n<meta property=\"og:description\" content=\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/nl\/2024\/05\/04\/sentynl\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-04T19:39:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T14:23:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)\",\"datePublished\":\"2024-05-04T19:39:27+00:00\",\"dateModified\":\"2025-01-29T14:23:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"},\"wordCount\":266,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"articleSection\":[\"News\",\"Uncategorized\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\",\"name\":\"Sentynl I The Progeria esearch Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"datePublished\":\"2024-05-04T19:39:27+00:00\",\"dateModified\":\"2025-01-29T14:23:02+00:00\",\"description\":\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/nl\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sentynl I The Progeria esearch Foundation","description":"Vanaf vrijdag 3 mei is Sentynl Therapeutics verantwoordelijk voor de productie en distributie van Zokinvy, de door de FDA goedgekeurde behandeling voor Progeria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/nl\/2024\/05\/04\/sentynl\/","og_locale":"nl_NL","og_type":"article","og_title":"Sentynl I The Progeria esearch Foundation","og_description":"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/nl\/2024\/05\/04\/sentynl\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2024-05-04T19:39:27+00:00","article_modified_time":"2025-01-29T14:23:02+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)","datePublished":"2024-05-04T19:39:27+00:00","dateModified":"2025-01-29T14:23:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"},"wordCount":266,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","articleSection":["News","Uncategorized"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/","url":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/","name":"Sentynl I The Progeria esearch Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","datePublished":"2024-05-04T19:39:27+00:00","dateModified":"2025-01-29T14:23:02+00:00","description":"Vanaf vrijdag 3 mei is Sentynl Therapeutics verantwoordelijk voor de productie en distributie van Zokinvy, de door de FDA goedgekeurde behandeling voor Progeria.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"De Progeria Research Stichting","description":"Voor de kinderen \u2665 Voor de genezing","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"De Progeria Research Stichting","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"Karen Betournay","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/nl\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/posts\/19165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/comments?post=19165"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/posts\/19165\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/media\/18808"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/media?parent=19165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/categories?post=19165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/nl\/wp-json\/wp\/v2\/tags?post=19165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}